Business Context and Reporting Period
This Form 8-K was filed by BioZone Pharmaceuticals, Inc. (not Cocrystal Pharma, Inc.) on March 1, 2012, reporting events occurring on February 24, 2012. The company is a Nevada corporation focused on pharmaceutical development. The filing primarily addresses unregistered sales of equity securities and the appointment of a new director.
Key Financial Metrics and Capital Structure
- Debt Issuance: The Company sold $1,700,000 of 10% secured convertible promissory notes on February 24, 2012, and an additional $600,000 on February 28-29, 2012, for total gross proceeds of $2,300,000.
- Debt Terms: Notes bear 10% annual interest, mature two years from issuance, and are convertible at an initial price of $0.20 per share.
- Warrants Issued: Warrants to purchase 8,500,000 shares (initial tranche) and 3,000,000 shares (additional tranche) were issued at an exercise price of $0.40 per share, expiring in ten years.
- Collateral: All obligations are secured by a first-priority security interest in all tangible and intangible assets of the Company.
- Use of Proceeds: Funds were used to repay outstanding promissory notes and for general working capital.
- Revenue and Profit: The filing text does not provide a clear value for revenue, profit, cash flow, or margins.
Material Changes and Corporate Actions
- Capital Raise: The Company completed a private placement of debt and warrants to accredited investors under Section 4(2) and Regulation D exemptions.
- Board Appointment: Elliot Maza, the current CEO and CFO, was appointed to the Board of Directors on February 24, 2012.
- Ownership Restrictions: Conversion of notes or exercise of warrants is restricted if the buyer would beneficially own more than 4.99% of the outstanding common stock.
Outlook, Risks, and Contingencies
- Default Risks: The Notes contain "Events of Default" clauses, including failure to pay accrued interest or breach of representations, which could make all amounts immediately due.
- Liquidity Strategy: The immediate use of proceeds to repay existing debt suggests a focus on stabilizing the balance sheet rather than immediate expansion.
- Registration Rights: Buyers have been granted "piggy-back" registration rights for 12 months, which may impact future share dilution if exercised.
Investor Verification Checklist
- Verify the exact amount of outstanding debt prior to this transaction to assess the net reduction in liabilities.
- Confirm the current share count to calculate the potential dilution from the 11,500,000 warrant shares and convertible notes.
- Review the Company's cash position to determine if the $2.3 million proceeds are sufficient to cover upcoming operational expenses and interest payments.
- Check for any subsequent filings regarding the repayment of the specific promissory notes mentioned as being retired.